These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 547147)

  • 21. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
    Takahashi N; Qi Y; Patel HR; Ahima RS
    J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body mass index as a predictor of hepatic steatosis in living liver donors.
    Rinella ME; Alonso E; Rao S; Whitington P; Fryer J; Abecassis M; Superina R; Flamm SL; Blei AT
    Liver Transpl; 2001 May; 7(5):409-14. PubMed ID: 11349260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of stanozolol in patients with pityriasis rubra pilaris and retinol-binding protein deficiency.
    Bergamaschini L; Tucci A; Colombo A; Agostoni A; Finzi AG; Altomare GF; Pigatto PD
    N Engl J Med; 1982 Mar; 306(9):546-7. PubMed ID: 7199120
    [No Abstract]   [Full Text] [Related]  

  • 24. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation.
    Rinella ME; McCarthy R; Thakrar K; Finn JP; Rao SM; Koffron AJ; Abecassis M; Blei AT
    Liver Transpl; 2003 Aug; 9(8):851-6. PubMed ID: 12884199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of stanozolol on 15nitrogen retention in the dog.
    Olson ME; Morck DW; Quinn KB
    Can J Vet Res; 2000 Oct; 64(4):246-8. PubMed ID: 11041505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass.
    Lima ML; Mourão SC; Diniz MT; Leite VH
    Obes Surg; 2005 May; 15(5):661-9. PubMed ID: 15946458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variceal hemorrhage in a case of hepatic steatosis.
    Madore P
    Am J Gastroenterol; 1970 Sep; 54(3):267-71. PubMed ID: 5311857
    [No Abstract]   [Full Text] [Related]  

  • 28. Hepatic steatosis associated with hepatitis C virus infection.
    Cornianu M; Dema A; Tăban S; Lazăr D; Lazăr E; Costi S
    Rom J Morphol Embryol; 2005; 46(4):283-9. PubMed ID: 16688364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of diabetic fatty liver with Buformin].
    Möller E
    Med Klin; 1967 Dec; 62(48):1873-6. PubMed ID: 5591974
    [No Abstract]   [Full Text] [Related]  

  • 30. Induced acute aflatoxicosis in goats: treatment with activated charcoal or dual combinations of oxytetracycline, stanozolol, and activated charcoal.
    Hatch RC; Clark JD; Jain AV; Weiss R
    Am J Vet Res; 1982 Apr; 43(4):644-8. PubMed ID: 6803625
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis.
    Gordon A; McLean CA; Pedersen JS; Bailey MJ; Roberts SK
    J Hepatol; 2005 Jul; 43(1):38-44. PubMed ID: 15876468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis.
    Adams LA; Angulo P; Abraham SC; Torgerson H; Brandhagen D
    Liver Int; 2006 Apr; 26(3):298-304. PubMed ID: 16584391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Liver pathology in gout].
    Tremel R; Pohl W
    Med Klin; 1971 May; 66(21):777-81. PubMed ID: 5578660
    [No Abstract]   [Full Text] [Related]  

  • 34. Increased liver mast cell recruitment in patients with chronic C virus-related hepatitis and histologically documented steatosis.
    Franceschini B; Russo C; Dioguardi N; Grizzi F
    J Viral Hepat; 2007 Aug; 14(8):549-55. PubMed ID: 17650288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development of hepatic steatosis].
    Girard JD; Hofstetter JR
    Helv Med Acta Suppl; 1969; 49():158-66. PubMed ID: 5267565
    [No Abstract]   [Full Text] [Related]  

  • 36. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.
    Tsochatzis E; Papatheodoridis GV; Manesis EK; Chrysanthos N; Kafiri G; Archimandritis AJ
    Dig Liver Dis; 2007 Oct; 39(10):936-42. PubMed ID: 17720637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fatty liver in newly diagnosed diabetes mellitus].
    Bauch K; Büttner W; Dempe A
    Dtsch Gesundheitsw; 1971 Oct; 26(44):2070-4. PubMed ID: 5143541
    [No Abstract]   [Full Text] [Related]  

  • 39. [Relationship between the severity of liver damage and the serum leptin level for nonalcoholic fatty liver disease].
    Kim KO; Park SH; Park CH; Han TH; Yoo KS; Kim JH; Lee MS; Kim DJ; Park CK; Cho HD
    Korean J Hepatol; 2005 Mar; 11(1):51-8. PubMed ID: 15788885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C.
    Vidali M; Occhino G; Ivaldi A; Rigamonti C; Sartori M; Albano E
    Am J Gastroenterol; 2008 Jan; 103(1):147-53. PubMed ID: 18184121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.